Atropos Health Has 12 New Peer-Reviewed Research Studies Across Numerous Disease States Published in First Half of 2026

Research focused on oncology, immunology, psychiatry, Crohn’s disease and More

PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, the world’s largest creator of real-world evidence (RWE) for clinical decision making, today announced that it has contributed to 12 new studies in the first six months of 2026, powered by high-quality real-world data from the Atropos Evidence™ Network and Atropos Health’s AI-driven real world evidence tools.

This new collection of research and conference presentations spans multiple disease states and demonstrates how real-world evidence accelerates clinically meaningful insights. A selection of these publications are summarized below and were presented at major conferences including ASCO 2026, the Society for Investigative Dermatology, the American Society of Clinical Psychopharmacology, ISPOR and Digestive Disease Week.

• Association between Semaglutide and Risk of Bone Fractures in Type 2 Diabetes - presented at ENDO2026 evaluated fracture incidence and body mass index (BMI) changes among type 2 diabetes patients treated with semaglutide versus dulaglutide or alternative weight loss drugs (phentermine/topiramate, bupropion/naltrexone). Overall, researchers found the semaglutide treatment was associated with a greater BMI reduction and 15% reduction in fracture incidence.
• Antidepressant Use and Melanoma Immunotherapy: An Unexpected Signal – presented at ASCO 2026 to examine whether SSRIs influence outcomes in patients with metastatic melanoma who receive immune checkpoint inhibitor therapy.
• mRNA vs. DNA COVID-19 Vaccines and Autoimmune Risk: Nuanced Findings from a Large Cohort – presented at the SID Annual Meeting 2026, the study found that there is a trend towards higher autoimmune risk after mRNA vaccination and should require additional research.
• Statins May Protect Against Intestinal Strictures in Crohn’s Disease – published in the Journal of Crohn’s and Colitis in March 2026, this study evaluated two national databases about how drug repurposing discovery, powered by real-world evidence can show secondary benefits.
• Alcohol Use Disorder: A Persistent Gap in Hospital Care – published in Alcohol and Alcoholism, the study showed that fewer than 3% of hospitalized patients with alcohol use disorder received any medication-assisted treatment.
• Machine Learning Targets Bipolar Disorder and Schizophrenia Treatment Selection – presented at ASCP Annual Meeting 2026. These two posters demonstrated how machine learning and real-world data can help identify which patients with bipolar 1 and schizophrenia could most likely benefit from the long-acting injectable, aripiprazole monohydrate.

These insights will continue to grow as Alexandria^®, the Atropos Evidence™ Library, which was already the largest source of novel medical content - with over 33M precision Evidence-Based Findings, is expected to grow to two billion pEBFs by the end of 2026. This increased scale will exceed all known medical evidence by 100x in volume.

“By utilizing our high-throughput evidence-creation tools, we are delivering robust, peer-reviewed real-world evidence at a scale and speed previously unimaginable,” said Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health. “These 12 new studies across diverse disease states demonstrate that we are doing more than generating data. We are filling the evidence gap with actionable, trusted insights that empower the entire healthcare ecosystem to make the best possible care decisions today. Atropos Health is fundamentally changing how care teams make daily medical decisions that are backed by high-quality evidence.”

This library is enabling the entire healthcare ecosystem - clinicians, researchers, life science partners, and others - to generate precise answers to complex medical questions quickly and improve patient and medical outcomes based on content not available anywhere else.

About Atropos Health

Atropos Health is closing medicine's most consequential gap: actionable evidence to inform the vast majority of clinical decisions that are made without evidence. By generating real-world evidence from actual patient outcomes and data, Atropos Health is building the evidence infrastructure that clinicians, life science researchers and AI platforms need to practice, develop and inform medicine, grounded in what actually works. Better healthcare is only possible with evidence, and Atropos Health is working to make it available for every patient, in every healthcare decision, every day. Atropos Health does this via GENEVA OS®, the operating system across a robust network of real-world data; Alexandria, the world’s largest evidence library; and evidence generation tools such as ChatRWD®, Green Button® and the Atropos Evidence™ Agent.

To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or X (Twitter).